CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (317)	9/28/2007 2:55:35 PM
From: mopgcw	of 411

mstar: CVTX announced Thursday that it has submitted its flagship drug, Ranexa, for a label expansion to include first-line treatment of chronic angina. We are leaving our fair value estimate unchanged as we had already anticipated the Food and Drug Administration submission. Although we think the FDA will approve Ranexa for first-line treatment, we still anticipate the majority of future sales to come from second-line use. Thanks to Ranexa's relatively poor safety profile and the efficacy of generic angina drugs, we think doctors will only prescribe Ranexa under certain conditions, such as when angina patients don't respond well to beta-blockers and nitrates. We think a first-line label expansion and Ranexa's good Phase III safety data should reassure doctors who already considered prescribing the drug as a second-line treatment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next